Health In Tech (HIT) Q2 2026 earnings review
Growth Narrative Collides with Reversing GAAP Revenue
Health In Tech is promoting forward-looking metrics like 'Contracted Revenue' and 'Pipeline Revenue' to distract from a troubling reality: GAAP revenue actually fell 13% YoY to $8.1M in Q2. Simultaneously, management is heavily spending on sales and marketing to capture market share, which caused net income to collapse from a $0.6M profit a year ago to a $2.5M loss today. The company reaffirmed its aggressive $45M-$50M full-year revenue guidance, but mathematically, this implies an unprecedented revenue acceleration in the second half of the year that is not yet supported by their own pipeline metrics.
🐂 Bull Case
The company successfully grew its distribution partners (brokers, TPAs, agencies) by 19.9% YoY to 933. If the platform is as sticky as management claims, this network represents significant latent revenue potential.
The upcoming HitRix platform and the contractually secured first employer for the Three-Year Rate Stabilization Program signal that the company's R&D phase is yielding tangible, marketable products.
🐻 Bear Case
Reaching the $47.5M guidance midpoint requires ~$30.7M in H2 revenue. However, the company's own explicit projections of contracted ($14.0M) plus expected pipeline conversion ($3.1M-$8.3M) only add up to ~$19.7M for H2.
Operating cash flow turned to a negative $6.2M in H1 2026 (down from a positive $2.0M in H1 2025). With cash reserves dropping to $6.5M, the company may face liquidity constraints if H2 revenue fails to materialize.
⚖️ Verdict: 🔴🔴
Highly Bearish. When a company changes its KPI focus to pipeline metrics right as GAAP revenue begins reversing, investors should be highly skeptical. The mathematical disconnect between management's H2 revenue expectations and their reaffirmed full-year guidance is a major red flag.
Key Themes
Mathematical Disconnect in Reaffirmed Guidance
Management reaffirmed FY26 revenue guidance of $45-$50M. Since H1 revenue was $16.8M, the midpoint requires $30.7M in H2. However, management explicitly stated they have $14.0M in H2 contracted revenue and expect $3.1M-$8.3M from the pipeline to hit 2026. At the midpoint, this totals $19.7M in expected H2 revenue. This creates an unexplained $11M gap required just to hit the midpoint of their reaffirmed guidance, raising severe credibility concerns.
GAAP Revenue is Reversing
Despite a positive narrative regarding pipeline expansion, Q2 revenue was $8.1M, representing a 13% YoY decline from $9.3M in Q2 2025. This contradicts the company's core narrative of explosive top-line growth driven by AI innovation and partner expansion.
Operating Expenses Surging Amidst Revenue Miss
The margin profile is decelerating aggressively. Q2 2026 gross profit collapsed by 38% YoY to $3.9M, while Sales & Marketing expenses nearly doubled (+80%) to $2.2M and G&A climbed 13% to $4.3M. This indicates negative operating leverage and suggests customer acquisition costs are spiking to combat falling organic sales.
HitRix Platform Launch
A specific technology driver for H2 2026 is the scheduled launch of HitRix, positioned as a next-generation AI marketplace. By utilizing AI document intelligence to automate data extraction, it expands beyond the eDIYBS system to cover the broader self-funded ecosystem, which management hopes will reignite conversion rates.
Distribution Network Expansion
The number of distribution partners is maintaining a stable, upward trajectory, growing 19.9% YoY to reach 933. Because the company relies entirely on a partner-led go-to-market strategy to access the 1 million+ US broker market, this leading indicator remains arguably the strongest fundamental growth engine.
Three-Year Rate Stabilization Program Gaining Traction
The company has officially secured its first employer group for the Three-Year Rate Stabilization Program and is actively engaged with high-profile governmental organizations for future participation. This acts as an antidote to a macro environment where traditional legacy carriers have historically sought 26-30% rate increases, positioning HIT as a budget-stabilizing alternative.
Other KPIs
Reversing sharply from a positive $2.01M in H1 2025. The company's cash position sits at $6.5M. While they recently completed a PIPE financing for $7M gross, the current burn rate indicates they could face a liquidity crunch before the end of the year if accounts receivable ($8.5M) are not collected swiftly.
Reversing from a positive $1.57M in Q2 2025. The company points to this as a deliberate strategic reinvestment into the sales and product teams, but the combination of rising OpEx and falling revenue paints a picture of deteriorating underlying unit economics.
Guidance
Accelerating. Implies approximately 35% to 50% YoY growth compared to FY25's $33.3M. Because H1 2026 revenue came in at only $16.8M, the midpoint of guidance ($47.5M) mathematically requires the company to achieve $30.7M in H2. This would require an extreme, historically unprecedented sequential acceleration that seems highly unlikely given the current 13% YoY decline seen in Q2.
Key Questions
Guidance Math Bridge
Your FY26 guidance implies over $30M in revenue in the second half, yet your contracted revenue and expected pipeline conversions for 2026 total under $20M for H2. What specific deals or unannounced products make up the $10M+ gap?
Reversing Top-Line
You highlight an expanding distribution network and strong pipeline metrics, but Q2 GAAP revenue actually declined 13% year-over-year. What caused this immediate organic revenue drop, and are brokers failing to convert quotes into binding policies?
Liquidity Runway
With cash reserves at $6.5M and a $6.2M operating cash burn in the first six months, do you anticipate needing to raise additional capital via equity or debt within the next two quarters?
Gross Margin Compression
Cost of revenues outpaced total revenue growth substantially this quarter, compressing gross profit to 48% of sales. Is this margin degradation structural due to the new product mix, or a temporary timing issue?